Discuss This Drug

ruxolitinib

CHEBI:CHEBI_66919

Definition

A pyrazole substituted at position 1 by a 2-cyano-1-cyclopentylethyl group and at position 3 by a pyrrolo[2,3-d]pyrimidin-4-yl group. Used as the phosphate salt for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

Chemical Information

Molecular Formula
C17H18N6
Molecular Mass
306.36500
Charge
0
SMILES
N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12
InChI
InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
InChIKey
HFNKQEVNSGCOJV-OAHLLOKOSA-N

Alternative Names

  • (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
  • INCB018424
  • ruxolitinib

Treatment Applications

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:66919
DRON_00010000
1193326
oboInOwl#hasDbXref
Wikipedia:Ruxolitinib

Additional References

Wikipedia:Ruxolitinib

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

core#notation
CHEBI:66919
listing_expiration_date
20241231
route
TOPICAL
marketing_start_date
20171129
spl_id
1d434e6e-bbe3-22fc-e063-6294a90ad5e6
package_ndc
54893-0509-1
package_description
20 kg in 1 DRUM (54893-0509-1)
labeler_name
STERLING SPA
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
1193326
oboInOwl#hasDbXref
Wikipedia:Ruxolitinib
oboInOwl#id
CHEBI:66919
generic_name
Ruxolitinib Hemifumarate
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
dosage_form
CREAM
product_ndc
54893-0509
brand_name
OPZELURA
brand_name_base
OPZELURA
application_number
NDA215309
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_76617
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
rxcui
2570757
active_ingredient_strength
1 kg/kg
package_marketing_start_date
21-JUL-23
nui
N0000190857
pharm_class_epc
Janus Kinase Inhibitor [EPC]
pharm_class
Janus Kinase Inhibitors [MoA]
pharm_class_moa
Janus Kinase Inhibitors [MoA]
active_ingredient_name
RUXOLITINIB HEMIFUMARATE
manufacturer_name
Incyte Corporation
unii
436LRU32H5
spl_set_id
24da5509-6631-4795-9d42-273faecd08e7
upc
0350881020605
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
has_treatment
http://purl.obolibrary.org/obo/DOID_8997
rdf-schema#range
https://w3id.org/def/predibionto#has_drug_113033
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect31569
owl#annotatedSource
t269890
owl#someValuesFrom
t3826076